Publisher
Springer Berlin Heidelberg
Reference40 articles.
1. Belloni B, Schonewolf N, Rozati S, Goldinger SM, Dummer R (2012) Cutaneous drug eruptions associated with the use of new oncological drugs. Chem Immunol Allergy 97: 191–202
2. Belum VR, Fischer A, Choi JN, Lacouture ME (2013) Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep 15: 249–259
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516
4. Degen A, Alter M, Schenck F, Satzger I, Volker B, Kapp A, Gutzmer R (2010) The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges 8: 652–661
5. Degen A, Alter M, Schenck F, Kapp A, Gutzmer R (2011) Kutane Nebenwirkungen der medikamentösen Tumortherapie. Hautarzt 62: 444–450